Scholarlink

<p>Fibroblast growth factor 21 (FGF21) levels are elevated with type 2 diabetes mellitus (T2D). This study aimed to elucidate whether FGF21 is a predictor for fragility fractures and to construct a predictive model using FGF21 as a risk factor to predict fractures in T2D. This prospective cohort study enrolled 371 individuals with high atherosclerotic risk, of whom 60.4% had T2D. FGF21 was measured at enrollment. The first incident fragility fractures were recorded. Individuals with T2D had a higher risk of major fractures (SHR 3.64, 95% CI 1.24–10.71) and tended toward a higher risk of any fractures (SHR 2.50, 95% CI 0.99–6.33). FGF21 was an independent risk factor for fractures in individuals with T2D. A predictive model comprising age, gender, 10-year probability of major osteoporotic fractures (FRAX-M) based on body mass index (BMI), FGF21, and aspartate transaminase (AST) demonstrated an AuROC of 0.84 and sensitivity and specificity of 84.2% and 74.5%, respectively, to predict fractures in T2D. The predictive risk score with the threshold of 103, which had an AuROC of 0.79, a sensitivity of 84.2%, and a specificity of 75.5%, was proposed for clinical application. In conclusion, FGF21 was a novel risk factor for fragility fractures in T2D. A predictive model and predictive risk score using age, gender, BMI-based FRAX-M, AST, and FGF21 showed high performance for predicting fractures in T2D. This predictive model may benefit clinical practice after further external validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FGF21 is a novel biomarker to predict fragility fractures in patients with type 2 diabetes mellitus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月14日

查看全文
  • Mattabhorn Phimphilai,
  • Arintaya Phrommintikul,
  • Wanwarang Wongcharoen,
  • Natavuth Hengjeerajarus,
  • Krittadhee Karndumri,
  • Nipon Chattipakorn,
  • Siriporn C. Chattipakorn

摘要

Fibroblast growth factor 21 (FGF21) levels are elevated with type 2 diabetes mellitus (T2D). This study aimed to elucidate whether FGF21 is a predictor for fragility fractures and to construct a predictive model using FGF21 as a risk factor to predict fractures in T2D. This prospective cohort study enrolled 371 individuals with high atherosclerotic risk, of whom 60.4% had T2D. FGF21 was measured at enrollment. The first incident fragility fractures were recorded. Individuals with T2D had a higher risk of major fractures (SHR 3.64, 95% CI 1.24–10.71) and tended toward a higher risk of any fractures (SHR 2.50, 95% CI 0.99–6.33). FGF21 was an independent risk factor for fractures in individuals with T2D. A predictive model comprising age, gender, 10-year probability of major osteoporotic fractures (FRAX-M) based on body mass index (BMI), FGF21, and aspartate transaminase (AST) demonstrated an AuROC of 0.84 and sensitivity and specificity of 84.2% and 74.5%, respectively, to predict fractures in T2D. The predictive risk score with the threshold of 103, which had an AuROC of 0.79, a sensitivity of 84.2%, and a specificity of 75.5%, was proposed for clinical application. In conclusion, FGF21 was a novel risk factor for fragility fractures in T2D. A predictive model and predictive risk score using age, gender, BMI-based FRAX-M, AST, and FGF21 showed high performance for predicting fractures in T2D. This predictive model may benefit clinical practice after further external validation.